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Reactivation of Hepatitis B Virus in Patients With Undetectable HBsAg 
Undergoing Chemotherapy for Malignant Lymphoma or Multiple Myeloma 
 
Reactivation of the hepatitis B virus (HBV) is a well-recognized complication following systemic 
chemotherapy for hematological malignancies. However, the incidence or risk factors of HBV 
reactivation remain unclear because only a few prospective cohorts have presented for this new clinical entity. 
The aim of this study was to clarify the frequency and risk factors of HBV reactivation in 
hepatitis B surface antigen (HBsAg) undetectable patients with malignant lymphoma or multiple 
myeloma, during or after chemotherapy. A total of 109 patients with undetectable HBsAg 
undergoing chemotherapy for malignant lymphoma or multiple myeloma were enrolled in this 
study. Anti-hepatitis B surface (anti-HBs) and anti-hepatitis B core (anti-HBc) were checked 
before treatment, and HBV DNA in sera was quantified monthly during and after chemotherapy. 
Out of 109 patients, 42 (38.5%) had anti-HBs and 59 (54.1%) had anti-HBc. Among the 59 
anti-HBc positive patients, four patients (4/59, 6.8%) showed HBV reactivation during 20.5 
median follow-up months. In all four patients with HBV reactivation, peripheral lymphocyte 
counts before chemotherapy were lower than those without HBV reactivation (P . 0.033). HBV 
reactivation occurred during and after chemotherapy containing rituximab for non-Hodgkin 
lymphoma. Four patients, who had HBV reactivation, did not develop de novo hepatitis due to 
HBV reactivation and were able to undergo chemotherapy against malignant lymphoma as 
scheduled. Monitoring of HBV DNA in sera is useful for the early diagnosis of HBV reactivation, 
and preemptive therapy is an useful 
alternative to prevent hepatitis due to HBV reactivation. Patients must be monitored 
periodically for HBV-DNA levels during and after chemotherapy. 
 
